Abstract: Epidermal growth factor receptor (EGFR) has been known to be a significant factor in the development and growth of many types of cancers. It is now accepted that the EGFR signal transduction net work plays an important role in multiple tumorigenic processes, contributing to cancercell proliferation, angiogenesis, and metastasis, as well as protection from apoptosis. Recently, EGFR monoclonal antibodies(McAb) and epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors have been validated as new treatment approach for those EGFR-positive cancers and have shown activity aginst advanced, chemofractory cancers in clinical trials. This article focuses on three EGFR targeted molecularly therapies of cancers.